TCGA-CN-5370-01A-01R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.05913242
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- ANGIOGENESIS+0.600
- INTERFERON_GAMMA_RESPONSE+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- INFLAMMATORY_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.500
- MYOGENESIS+0.460
- COMPLEMENT+0.410
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.420
- DNA_REPAIR-0.320
- MYC_TARGETS_V1-0.230
- CHOLESTEROL_HOMEOSTASIS-0.170
- E2F_TARGETS-0.170
- PEROXISOME-0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.140
- FATTY_ACID_METABOLISM-0.130
- HEME_METABOLISM-0.120
- MYC_TARGETS_V2-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.923 |
| 2 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.915 |
| 3 | aMVAC.P_012_TURBT_S230 | — | — | 0.914 |
| 4 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.914 |
| 5 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.912 |
| 6 | MDT-AP-3277 | Med | Medulloblastoma | 0.904 |
| 7 | TCGA-CV-7104-01A-11R-2016-07 | — | — | 0.901 |
| 8 | MDT-AP-3156 | Med | Medulloblastoma | 0.898 |
| 9 | MDT-AP-2029 | Med | Medulloblastoma | 0.896 |
| 10 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| MYOGENESIS | 0.460 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |